Sulpiride versus Haloperidol, a Clinical Trial in Schizophrenia. A preliminary report

  title={Sulpiride versus Haloperidol, a Clinical Trial in Schizophrenia. A preliminary report},
  author={E. Munk‐Andersen and Kirsten Behnke and Jon Heltberg and H Nielsen and Jes Gerlach},
  journal={Acta Psychiatrica Scandinavica},
Abstract Sixteen out of 25 hebephrenic and paranoid schizophrenic patients completed a double‐blind cross‐over study with sulpiride and haloperidol. The patient sample was relatively chronic: Median age was 35 years (range 26–53 years), median duration of illness 10 years (4–35 years), and median duration of neuroleptic treatment 5 years (1–28 years). Each patient was treated with sulpiride/haloperidol in random order for 12 weeks with a drug‐free period before each treatment phase. 
20 Citations

Dose finding and serum concentrations of neuroleptics in the treatment of schizophrenic patients.

In a survey of the best maintenance doses of neuroleptics in schizophrenics, Baldessarini and Davis (1980) did not find a dose-effect relationship among dose equivalents of about 100–2500 mg chlorpromazine per day.

Sulpiride and placebo in depressed elderly outpatients: A double‐blind study

The results showed that sulpiride in small doses had no antidepressant effects on elderly patients suffering from relatively mild degrees of depression, i.e. from dysthymic disorder (chronic depression) or atypical depression.

Sulpiride for schizophrenia.

Sulpiride may be an effective antipsychotic drug but evidence is limited and data relating to claims for its value against negative symptoms is not trial-based.

Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.

A high-quality systematic review of the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotic drugs in schizophrenia and schizophrenia-like psychosis found that haloperIDol alleviated more positive symptoms of schizophrenia than the other antipsychotics.

Sulpiride: an Antipsychotic with Selective Dopaminergic Antagonist Properties

A unique pharmacology does not appear to provide sulpiride with a greater effectiveness than the standard antipsychotics, but may provide it with minor safety advantages.

A Risk-Benefit Assessment of Sulpiride in the Treatment of Schizophrenia

Sulpiride could find its specific therapeutic role in elderly patients with schizophrenia, as it shows a good margin of safety between therapeutic dosages and toxic concentrations, and its low incidence of extrapyramidal adverse effects.

Pharmacological data of the atypical neuroleptic compound melperone (Buronilr̀)

  • E. Christensson
  • Psychology, Biology
    Acta psychiatrica Scandinavica. Supplementum
  • 1989
Melperone is potent in blocking amphetamine induced locomotion, exploratory behaviour, L‐Dopa induced jumping and aggression suggesting a limbic mode of action and a weak effect of melperone on striatal DA neurotransmission.



Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine.

Comparison of sulpiride and chlorpromazine in psychoses

In a material of 71 patients admitted because of acute or chronic psychoses, 32 patients treated with sulpiride and 39 with chlorpromazine, the effect of the two preparations was very similar as were the type and frequency of side effects, except that sulpirides did not cause sunrash.

An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.

It appears that central dopaminergic blockade in the hypothalamic area is not a prerequisite for antipsychotic activity and sulpiride has a low potential for producing tardive dyskinesia.

Effects of chronic treatment with l-sulpiride and haloperidol on central monoaminergic mechanisms.

Chronic treatment with l-sulpiride and haloperidol for 2 weeks produced behavioral signs of DA receptor supersensitivity in both the striatum and the nucleus accumbens-tuberculum olfactorium region, and 48 hr after treatment apomorphine-induced locomotion, total activity, and rearing activity was significantly enhanced.

Antipsychotic drugs, neurotransmitters, and schizophrenia.

  • A. Carlsson
  • Psychology, Medicine
    The American journal of psychiatry
  • 1978
Although a primary disturbance in dopamine function in schizophrenia cannot be ruled out, the intimate relationship between dopaminergic and other neuronal systems must be emphasized and the possible involvement of other amine, amino acid, or peptide transmitters in schizophreniaannot be disregarded.


The central action of sulpiride differs from that of classic neuroleptics in that this drug stimulates dopamine turnover without producing catalepsy.

The Brief Psychiatric Rating Scale

A substantial, specific abnormality in CSPG expression by astrocytes is pointed out that may contribute disruption of the function of neurones and glial cells of the amygdala and the entorhinal cortex in schizophrenia.

Acquiescence, Social Desirability and Inhibition Reflected by “Response Set” Scales

In 1954 1 became interested in the fact that, if a number of items were selected at random in a personality inventory and each scored in the same direction, say "false," then the resulting total

Multiple receptors for dopamine

Pharmacological and biochemical criteria can be used to separate those dopamine receptors which are linked to the enzyme adenylyl cyclase and those which are not.

Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial.